Drugs / Anti-NY ESO-1 TCR-transduced T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02457650 | Apr 2015 → Dec 2019 | breast cancer, carcinoma of esophagus, lung cancer, melanoma +6 | Shenzhen Second People's Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-NY ESO-1 TCR-transduced T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02457650 ↗ |
| Action | Deplete | “NY-ESO-1 specific T cells will only recognize and kill NY-ESO-1-expressing cancer cells” NCT02457650 ↗ |
| Modality | Cell therapy | “Autologous T cells engineered to express a T cell receptor (TCR) targeting NY-ESO-1 will be infused back to patients” NCT02457650 ↗ |
| Route | Intravenous | “Modified cells will be infused IV over 30 minutes.” NCT02457650 ↗ |